A Phase 3 interventional study of Abemaciclib and Standard Adjuvant ET in Breast Neoplasms, sponsored by Eli Lilly and Company. Terminated at 115 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.
Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 29th largest by enrollment, is one of 7 that started in 2021, is one of 11 in phase 3, and was the 33rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Japanese Foundation for Cancer Research · Sites in Japan
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 29 · Phase 3 11 · Phase 4 8
First in 2014; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 55 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 55 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 45th largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 in phase 3, and was the 76th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
6 of the studies testing abemaciclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06341621Phase 3Fudan UniversityChemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib | 2027-02-25 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT06207734Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDiscontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | 2027-01-10 |
| NCT04614194University of Texas Southwestern Medical CenterSingle Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | 2027-04-15 |
| NCT04305834City of Hope Medical CenterAbemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 55 studies testing abemaciclib in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). Your participation could last up to 10 years depending on how you and your tumor respond.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have received one of the following eligible HER2-targeted adjuvant regimens AND be randomized within 12 weeks of completing the regimen:
Have high risk disease, defined by one of the following criteria:
Those who received neoadjuvant chemotherapy along with HER2-targeted treatment must have:
Those who had definitive surgery prior to systemic therapy and completed adjuvant chemotherapy along with HER2-targeted therapies (trastuzumab and pertuzumab) must have
Exclusion Criteria:
Have breast cancer with any of the following features:
Have other medical conditions including:
Have previously received treatment with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 150 milligrams (mg) of abemaciclib administered twice daily (BID) orally along with standard adjuvant endocrine therapy (ET).
Drug: Abemaciclib · Drug: Standard Adjuvant ET
Participants received placebo administered BID orally along with standard adjuvant ET.
Drug: Standard Adjuvant ET · Drug: Placebo
Administered orally.
Also known as: LY2835219
Administered according to label instructions.
Administered orally.
Invasive Disease Free Survival (IDFS)
IDFS, as defined by the STEEP System, is measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
Time frame: Randomization to Recurrence or Death from Any Cause (up to 890 days)
Overall Survival (OS)
OS is defined as the time from randomization until death from any cause. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
Time frame: Randomization to Death from Any Cause (up to 890 days)
Distant Relapse-Free Survival (DRFS)
DRFS is defined as the time from randomization to distant recurrence or death from any cause, whichever occurs first. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
Time frame: Randomization to Distant Recurrence or Death from Any Cause (up to 890 days)
Percentage of Participants With Central Nervous System (CNS) Metastases as First Site of Disease Recurrence
Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
Time frame: Randomization to Distant Recurrence or Death from Any Cause (up to 890 days)
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Scale Score
The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation will be applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
Time frame: Cycle 1 up to 390 days
Change From Baseline in the EuroQOL 5 Dimension 5 Level (EQ-5D 5L) Index Score
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which are anchored on a scale of 0 to 1 with a higher score representing better health status. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
Time frame: Cycle 1 up to 390 days
Pharmacokinetics (PK): Mean Steady State Concentrations of Abemaciclib
Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
Time frame: Day 1 of Cycles 1-3 (Cycle = 28 days)
The study was terminated early due to inability to enroll study participants. Data was not collected after termination and outcome measures were not assessed.
| Milestone | 150 mg Abemaciclib + Endocrine Therapy (ET) | Placebo + ET |
|---|---|---|
| Started | 55 | 56 |
| Received at least one dose of study drug | 55 | 56 |
| Completed | 25 | 0 |
| Not completed | 30 | 56 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Disease relapse | 1 | 0 |
| Withdrew: Non-compliance with study drug | 2 | 0 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Study terminated by irb/erb | 0 | 2 |
| Withdrew: Study terminated by sponsor | 10 | 48 |
| Withdrew: Withdrawal by subject | 11 | 3 |
IDFS, as defined by the STEEP System, is measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
No measurements were reported for this outcome.
OS is defined as the time from randomization until death from any cause. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
No measurements were reported for this outcome.
DRFS is defined as the time from randomization to distant recurrence or death from any cause, whichever occurs first. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
No measurements were reported for this outcome.
Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
No measurements were reported for this outcome.
The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation will be applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
No measurements were reported for this outcome.
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which are anchored on a scale of 0 to 1 with a higher score representing better health status. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
No measurements were reported for this outcome.
Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.
No measurements were reported for this outcome.
Collected over Baseline Up To 890 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 150 mg Abemaciclib + ET | 0/55 (0%) | 6/55 (10.9%) | 53/55 (96.4%) |
| Placebo + ET | 0/56 (0%) | 2/56 (3.6%) | 40/56 (71.4%) |
| Event | 150 mg Abemaciclib + ET | Placebo + ET |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/55 | 0/56 |
| Anal abscessInfections and infestations | 1/55 | 0/56 |
| Covid-19Infections and infestations | 1/55 | 0/56 |
| Radius fractureInjury, poisoning and procedural complications | 1/55 | 1/56 |
| Alanine aminotransferase increasedInvestigations | 1/55 | 0/56 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/55 | 0/56 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/54 | 1/56 |
| Event | 150 mg Abemaciclib + ET | Placebo + ET |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 44/55 | 5/56 |
| NeutropeniaBlood and lymphatic system disorders | 28/55 | 4/56 |
| LeukopeniaBlood and lymphatic system disorders | 17/55 | 3/56 |
| NauseaGastrointestinal disorders | 17/55 | 8/56 |
| FatigueGeneral disorders | 16/55 | 6/56 |
| AnaemiaBlood and lymphatic system disorders | 13/55 | 1/56 |
| Covid-19Infections and infestations | 13/55 | 8/56 |
| ThrombocytopeniaBlood and lymphatic system disorders | 12/55 | 0/56 |
| Abdominal painGastrointestinal disorders | 12/55 | 6/56 |
| VomitingGastrointestinal disorders | 11/55 | 1/56 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | 150 mg Abemaciclib + ET | Placebo + ET | Total |
|---|---|---|---|
| Mean | 48.60 ± 11.76 | 49.70 ± 11.17 | 49.20 ± 11.43 |
| Sex: Female, Male(Participants) | 150 mg Abemaciclib + ET | Placebo + ET | Total |
|---|---|---|---|
| Female | 54 | 56 | 110 |
| Male | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | 150 mg Abemaciclib + ET | Placebo + ET | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 12 | 21 |
| Not Hispanic or Latino | 44 | 41 | 85 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Race (NIH/OMB)(Participants) | 150 mg Abemaciclib + ET | Placebo + ET | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 26 | 23 | 49 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 27 | 29 | 56 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | 150 mg Abemaciclib + ET | Placebo + ET | Total |
|---|---|---|---|
| Argentina | 4 | 5 | 9 |
| Australia | 1 | 1 | 2 |
| Austria | 0 | 1 | 1 |
| Belgium | 2 | 2 | 4 |
| Brazil | 3 | 3 | 6 |
| China | 12 | 15 | 27 |
| France | 2 | 0 | 2 |
| Germany | 2 | 1 | 3 |
| Greece | 4 | 4 | 8 |
| Hungary | 1 | 0 | 1 |
| Israel | 1 | 0 | 1 |
| Italy | 1 | 1 | 2 |
| Japan | 7 | 3 | 10 |
| Mexico | 1 | 1 | 2 |
| South Korea | 4 | 2 | 6 |
| Spain | 3 | 5 | 8 |
| Switzerland | 0 | 2 | 2 |
| Taiwan | 1 | 3 | 4 |
| United Kingdom | 1 | 4 | 5 |
| United States | 5 | 3 | 8 |
Showing the first 100 of 115 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2021 to primary completion in Jun 2024, 37 months.
Results were first posted in Jul 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib